About Us
Products
Responsibility
Investors
Media
Careers
Worldwide
- North America
  - USA
  - Canada
  - Mexico
- South America
  - Brazil
  - Peru
- Asia Pacific
  - India
  - Bangladesh
  - Thailand
  - Malaysia and Singapore
  - Myanmar
  - Sri Lanka
  - Japan
  - China
- Europe
  - Denmark
  - Finland
  - France
  - Germany
  - Hungary
  - Italy
  - Norway
  - Poland
  - Romania
  - Spain
  - Sweden
  - Switzerland
  - The Netherlands
  - The United Kingdom & Ireland
- Middle East
  - UAE
- Africa
  - Morocco
  - Nigeria
  - South Africa
  - Egypt
- Oceania
  - Australia & New Zealand
- CIS
  - Russia
  - Ukraine
Contact Us

Select Page

Sun Pharma reports Q1FY26 results

by ananthi | Jul 31, 2025 | Press Releases | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Search for:

Recent Posts

Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
Sun Pharma Comes on Board as Principal Sponsor and Health Partner of Royal Challengers Bengaluru (RCB) for T20 Season 2026
Sun Pharma reports Q3FY26 results
Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management
Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

Recent Comments

About Sun Pharma
- Vision & Values
- Milestones & Recognitions
Operations
Investors
Work with us
- Careers
- Current Openings
Quick Links

Facebook
X
Instagram
Linkdin
Instagram

Copyright © Sun Pharmaceutical Industries Ltd. Privacy Policy | Disclaimer

Top

Important Notice

As per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 it is mandatory for all the shareholders holding shares in physical form to update their KYC and other details.